oncology.pencis.com/”> A group of researchers at the University of Queensland (UQ), Australia, has recently developed an innovative Nanoparticle-based Conference-terms-conditions/”>Drug Delivery system that may help to overcome some of the challenges associated with Conference-terms-conditions/”>Drug Delivery for certain brain cancers.
oncology.pencis.com/”>Treating brain cancer effectively presents a series of challenges. For instance, certain Award-call-for-profile/”>Chemotherapy drugs are high in toxicity and have a limited lifespan in the Blood. Thus, developing new technologies for delivering such drugs is vital when it comes to ensuring patients get the most out of the therapeutic effects of the drugs.
oncology.pencis.com/”>Published in the Journal of Controlled Release, the team describes how they created a silica Nanoparticle that can carry temozolomide, a Award-call-for-profile/”>Chemotherapy drug typically used for treating malignant gliomas or glioblastomas. oncology.pencis.com/”>Loaded Nanoparticles
oncology.pencis.com/”>Temozolomide was first approved for use in the EU and United States in 1999 and has proven to be an effective treatment for treating malignant tumors when exposed to the site of treatment consistently. However, achieving this successfully is also one of the main challenges that medical professionals face.
oncology.pencis.com/”>This Award-call-for-profile/”>Chemotherapy drug has limitations – it doesn’t stay in the Blood for very long, it can be pushed out of the brain, and it doesn’t have high penetration from Blood into the brain.
oncology.pencis.com/”>Dr. Taskeen Janjua, University of Queensland
oncology.pencis.com/”>By loading silica nanoparticles with temozolomide, the team was able to create a more efficient Conference-terms-conditions/”>Drug Delivery system.
oncology.pencis.com/”>To make the drug more effective, we developed an ultra-small, large pore Nanoparticle to help it move through the Blood-brain barrier and penetrate the tumor while also reducing unwanted patient side effects.
oncology.pencis.com/”>Dr. Taskeen Janjua, University of Queensland
oncology.pencis.com/”>Related Storiesoncology.pencis.com/”>cancer Cooking Lesson, A Basic Look At How Nanotechnology Can Be Used To Physically Destroy cancer Cells and Cure The Body of cancer oncology.pencis.com/”>Nanoparticles Mediate Therapeutic Protein Delivery for Brain Injury Treatment oncology.pencis.com/”>Nanoplatforms in Imaging-Guided Brain Tumor Treatment
oncology.pencis.com/”>In the trials, the team used multi-cellular 3D spheroids to mimic responses and interactions in brain tumor cells when exposed to the loaded silica nanoparticles. The team found that this system has the potential to penetrate the brain-Blood barrier and deliver temozolomide directly into the tumor. oncology.pencis.com/”>Improving Brain cancer Treatment Strategies
oncology.pencis.com/”>Improving the ability to treat malignant glioblastomas is crucial as they are amongst the most aggressive and common forms of brain cancer with no known specific cause. In most cases, the chances are relatively high that patients will fall into remission due to the nature of these tumors and the limitations of current Conference-terms-conditions/”>Drug Delivery systems.
oncology.pencis.com/”>However, the team claims that this ground-breaking approach could not only improve the delivery of temozolomide but also could, in effect, improve the long-term potential of recovery as it may even prevent the cancer from returning.
oncology.pencis.com/”>Moreover, when treating their test animal models, the team discovered that the silica nanoparticles were able to reach the brain of the mice in just a few hours and had no negative impact on any other major organs in the body.
oncology.pencis.com/”>This innovative Conference-terms-conditions/”>Drug Delivery system has the potential to improve the effectiveness of brain cancer treatment and could lead to new and better treatments for this devastating disease.
oncology.pencis.com/”>Dr. Popat, Associate Professor, University of Queensland
oncology.pencis.com/”>Although brain cancers are not among the most common forms, they can be devastating as survival chances are lower than other forms of cancer, with the likelihood of surviving more than five years post-diagnosis being less than 23%.1
oncology.pencis.com/”>While the UQ team says more Research is required to further develop the silica-based NanoparticleConference-terms-conditions/”>Drug Delivery system, the results are promising.
oncology.pencis.com/”>This preclinical Research will accelerate future clinical development of a promising health technology and further the goal of improving outcomes for patients with brain cancer.
oncology.pencis.com/”>Dr. Popat, Associate Professor, University of Queensland oncology.pencis.com/”>References and Further Reading
oncology.pencis.com/”>oncology.pencis.com/”>Nanoparticles deliver brain cancer treatment (2023) UQ News. Available at: https://www.uq.edu.au/News/article/2023/05/nanoparticles-deliver-brain-cancer-treatment
I’m struggling to see the subject of cancer raised anywhere in mainstream news these days. However that doesn’t mean that the issues have disappeared. Quite the reverse of course. The situation for all of us is worsening by the day, but that doesn’t stop us from trying to improve things for our children and grandchildren. In my work I get to speak to so many wonderful people doing just that, and one of these is Lynette. She is looking for help to solve on of the biggest current inequalities in cancerwithin the UK
“My name is Lynette and I am a trainee clinical psychologist from Canterbury Christ Church University, UK. I am conducting a research looking into the experiences of cancer and cancer care amongst young people from ethnically minoritised backgrounds.
cancer health disparities across different ethnic groups have been widely documented. In particular, low awareness of cancer symptoms, low participation in cancer screening programmes and delayed help seeking behaviours were more likely to be found in ethnically minoritised groups. Many patient experience studies have highlighted reports of poorer experiences of cancer care, quality of life and health outcomes amongst these ethnically minoritised populations. These aspects of cancer experience have been shown to be associated with cultural beliefs, misconceptions and stigma around cancer, for instance barriers to help-seeking, adjustment to diagnosis, illness disclosure and coping strategies.
Whilst there is a growing body of research shedding light on the lived experiences of ethnically minoritised adult cancer patients, only little research has been undertaken with the younger population. When presented with a life changing physical health condition during this developmental trajectory, adolescents and young adults are confronted with significant psychosocial challenges that interfere with their roles in relation to family relations, peer networks, education, employment and future aspirations. Research has shown that ethnically minoritised young people with cancer are more likely to have additional unmet needs, poorer quality of life and experiences of care. This population is faced with a ‘double disparity’, where they have to cope with cancer amongst challenges at a transitional age in tandem with barriers associated with identifying as ethnically marginalised. Yet there is little research looking into the challenges and unmet needs these young people face. I am interested in learning from young people’s personal experiences to help us understand better ways of supporting them in the service.“
Looking for young people to help us improve cancer care.(UK only)
oncology.pencis.com/”>Precision medicine is transforming cancer treatment by tailoring therapies to the unique genetic makeup of each individual’s cancer.
oncology.pencis.com/”>Genetic testing and molecular profiling enable oncologists to identify specific mutations and biomarkers, allowing for targeted therapies that attack cancer cells while minimizing harm to healthy cells. This approach has shown promising results, leading to improved treatment outcomes and reduced side effects. oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy: Harnessing power of immune system
oncology.pencis.com/”>Conference-registration-euro/”>immunotherapy has emerged as a groundbreaking treatment option that utilizes the body’s immune system to fight cancer.
oncology.pencis.com/”>It involves stimulating the immune system to recognize and destroy cancer cells. Checkpoint inhibitors, CAR-T Conference-sponsor/”>cell therapy and cancer vaccines are among the notable Conference-registration-euro/”>immunotherapy techniques that have shown remarkable success in treating various cancers and prolonging patient survival. oncology.pencis.com/”>Liquid biopsies: Non-invasive cancer detection and monitoring
oncology.pencis.com/”>Liquid biopsies offer a non-invasive method for detecting and monitoring cancer. By analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs) or other biomarkers present in Blood or other body fluids, liquid biopsies can provide valuable information about tumor characteristics, treatment response and potential resistance.
oncology.pencis.com/”>This approach is revolutionizing early cancer detection, monitoring treatment effectiveness and guiding personalized treatment decisions. oncology.pencis.com/”>Targeted therapies: Disrupting cancer-specific pathways
oncology.pencis.com/”>Targeted therapies focus on specific molecules or pathways involved in cancer growth and survival.
oncology.pencis.com/”>By directly interfering with these cancer-specific targets, these therapies can effectively inhibit tumor growth and progression. Advancements in understanding tumor biology and development of targeted therapies have led to significant breakthroughs, particularly in cancers with specific mutations or genetic alterations. oncology.pencis.com/”>Artificial intelligence and machine learning: Assisting diagnosis and treatment
oncology.pencis.com/”>Artificial intelligence and machine learning algorithms are being utilized to analyze vast amounts of patient data and assist in cancer diagnosis, prognosis and treatment planning.
oncology.pencis.com/”>These technologies can identify patterns and provide valuable insights for healthcare professionals, leading to more accurate and personalized treatment strategies. AI-powered imaging techniques also aid in early detection and precise tumor delineation.
oncology.pencis.com/”>The field of cancerResearch and treatment is rapidly advancing, bringing new hope to patients and transforming the way we approach this complex disease and revolutionizing cancer care.
oncology.pencis.com/”>As these innovations continue to evolve, they hold the potential to improve patient outcomes, increase survival rates and eventually bring us closer to a world where cancer is no longer a formidable threat.
oncology.pencis.com/”>It’s important to note that while these advances have tremendous promise, they may not be applicable to all cancer types or individuals. Each patient’s treatment plan should be tailored to their specific diagnosis, characteristics and medical history.
oncology.pencis.com/”>Consulting with healthcare professionals and oncologists is crucial for personalized guidance and decision-making regarding the latest advancements in cancerResearch and treatment.
Richard A. Larson, MD, is a professor of medicine in the Section of Hematology/oncology and director of the Hematologic Malignancies Clinical Research Program at the University of Chicago. He received his medical degree from the Stanford University School of Medicine and completed his postdoctoral training in Internal Medicine, Hematology, and Medical oncology at the University of Chicago. Dr. Larson is also a member of the 2023 cancer.Net Editorial Board. View Dr. Larson’s disclosures.
A Blood transfusion is a medical procedure to give Blood, or parts of the Blood, to someone who needs it. Some people may need a Blood transfusion if they have a medical condition, such as cancer, that affects how the body produces Blood cells. They may also require a Blood transfusion if they lose Blood after surgery or are experiencing other causes of bleeding.
Here, learn more about why you might receive a Blood transfusion during cancer, what to expect during a Blood transfusion, and what to know about the side effects you may experience after receiving a transfusion.
Why might someone with cancer need a Blood transfusion?
People with cancer may require a Blood transfusion for various reasons, depending on their specific condition and treatment. These reasons might include:
Chemotherapy-induced Anemia.Chemotherapy can suppress the bone marrow’s ability to produce red Blood cells, leading to Anemia. Anemia is when you have a low level of red Blood cells in your body. Blood transfusions replenish the red Blood cell count and can relieve symptoms such as fatigue, weakness, and shortness of breath.
Surgery-related Blood loss. cancer surgery can cause bleeding, and if the patient’s Blood volume drops too low, a Blood transfusion may be needed to restore it to a safe level.
Bone marrow failure and Thrombocytopenia (low platelet count). Certain cancers, such as leukemia or myeloma, predominantly affect the bone marrow and interfere with the production of normal Blood cells. This is called “pancytopenia.” These diseases, as well as Chemotherapy, can interfere with the normal production and function of platelets, which help the Blood to clot. Platelet transfusions can help prevent or control bleeding episodes in these patients.
Support during a bone marrow transplant. Before a bone marrow transplant, a person typically received high-dose Chemotherapy and/or radiation therapy, which can damage the bone marrow and reduce its ability to produce Blood cells. Then, during a bone marrow transplant, the diseased bone marrow is replaced by healthy stem cells from the donor. Blood transfusions may be necessary during this period to support the patient until the transplanted stem cells begin to function and produce new Blood cells.
What are the different types of Blood transfusions?
Blood is made up of different parts, or components. These components include the liquid plasma, red Blood cells, white Blood cells, and platelets. Transfusion of whole Blood is less common than transfusion of one of the Blood components. For most types of Blood transfusions, the Blood used comes from a donor. Special measures are used to ensure that Blood donation is safe for both recipients and donors.
The different types of Blood transfusion that your doctor may recommend during cancer and its treatment include:
Plasma is the liquid part of Blood that carries the Blood cells. It contains proteins that help the Blood clot. It can be frozen and stored. A plasma transfusion can be given to people who have bleeding disorders, certain types of cancer, or liver disease. It may also be given after surgery if the person had considerable Blood loss.
Red Blood cells are made in the bone marrow and carry oxygen to the tissues in the body. Red Blood cells contain hemoglobin, which is a protein that carries oxygen and gives Blood its red color. Bleeding that is caused by trauma, surgery, or certain diseases may lead to a low red Blood cell count. If a person has a low red Blood cell count, a red Blood cell transfusion may be needed. A red Blood cell transfusion is usually given when a person’s red Blood cell count or hemoglobin level drops low enough to cause symptoms such as dizziness, fatigue, or shortness of breath.
A low platelet count is called Thrombocytopenia. A platelet transfusion may be needed if the bone marrow cannot make enough platelets, which may occur during cancer or its treatment. There is a risk of spontaneous bleeding if a person’s platelet count falls too low. Platelets may be given in advance if there is an increased risk of bleeding from a surgical procedure. Sometimes, platelet transfusions are not needed despite a low platelet count if there are no signs of bleeding.
White Blood cells help the body fight infection. Granulocyte transfusions are rarely given. They are usually reserved for people who have a very low white Blood cell count, called leukopenia or neutropenia, as well as for people who have a severe infection that doesn’t respond to antibiotics. Instead of transfusing white Blood cells, doctors commonly give injections of white Blood cell growth factors that stimulate the body to make its own white Blood cells.
In some cases, a person can serve as their own Blood donor. When someone donates their Blood for their own use, it is called an “autologous Blood donation” or “autotransfusion.” People may donate their own Blood before undergoing surgery in case they need a Blood transfusion during or after the procedure. Generally, Blood can be stored for up to 42 days.
Blood products that are used in transfusions are treated in special ways to make them safe and to prevent reactions in the recipient. Blood products may be treated with radiation before they are transfused. Radiation doesn’t affect red Blood cells or platelets, but it stops white Blood cells from functioning. Special Blood filters may also be used that help remove white Blood cells. This process is called “leukocyte reduction,” and it is used to help prevent a reaction in Blood transfusion recipients.
If your doctor has recommended that you receive a Blood transfusion, you will have a Blood test to find out your Blood type and Rhesus (Rh) factor. There are 4 Blood types: A, B, AB, or O. The Rh factor is an antigen that is found on the surface of some red Blood cells, making the cells “Rh-positive.” This information is important to know so that you receive Blood from a donor who matches your Blood type and Rh factor.
The Blood bank takes important precautions to prevent the recipient from having a reaction to the donated Blood. They cross-match the donor’s Blood to check that it matches and is compatible with the recipient’s Blood type. The health care team also carefully checks the donated Blood to make sure the right type of Blood is given to the right person. Before a transfusion, you may be given acetaminophen or antihistamines, such as diphenhydramine, to help prevent mild reactions.
During a Blood transfusion, an intravenous (IV) needle is inserted into a vein in your hand or arm. A bag of specially selected and matched Blood cells is hung on a pole, and the Blood flows from the bag through the IV and into your vein. Most of the time, people don’t feel any discomfort when the Blood goes in. However, the Blood is refrigerated, so it may feel a little cold.
During the transfusion, the nurse will monitor your temperature, Blood pressure, and heart rate. The nurse will also watch for any rash or signs of an allergic reaction. A red Blood cell transfusion usually takes between 2 and 3 hours. Platelet transfusions are shorter.
What are the possible side effects of a Blood transfusion?
A Blood transfusion is typically a very safe procedure, and the benefits of receiving a transfusion typically outweigh the possible risks. Adults or children who have received several Blood transfusions may have a higher risk of reacting to later Blood transfusions.
The health care team will watch you closely during a Blood transfusion to monitor for possible side effects. Although uncommon, some side effects that may occur during or after a Blood transfusion include:
Fever, chills, headache, or nausea. These symptoms can be caused by a reaction between the recipient’s immune system and the cells or proteins from the donated Blood. When this happens, the nurse may stop the transfusion and give a fever-reducing medicine. When the person’s temperature is back to normal, the transfusion can usually continue.
Allergic reaction. An allergic reaction can occur if the recipient’s immune system reacts to proteins in the donated Blood. These reactions may include hives or itching. In rare cases, a Blood transfusion can cause anaphylaxis, which is a severe and sometimes life-threatening allergic reaction. If an allergic reaction occurs, the transfusion is stopped and allergy medicines such as antihistamines and steroids are given. If the reaction is mild, the transfusion can start again. If the reaction is more serious, the transfusion is stopped.
Hemolytic reaction. This type of reaction is very rare but can occur when the donor’s and recipient’s Blood types do not match. During a hemolytic reaction, the recipient’s antibodies attack the transfused red Blood cells, causing them to break down, or hemolyze. The recipient develops fever, chills, or chest and lower back pain. This reaction can be mild or more severe. If severe, a hemolytic reaction can result in kidney damage or even death.
Transfusion-related acute lung injury (TRALI). This is a reaction of the recipient’s immune system to substances in the transfused Blood. TRALI damages lung tissue and causes fluid to accumulate in the lungs. TRALI may be immediate or delayed and causes difficulty breathing. Treatment for TRALI may include being given oxygen.
Circulatory overload. This occurs when the recipient’s circulatory system has too much Blood volume in it, which can cause difficulty breathing and heart failure. Circulatory overload is more likely to occur in older individuals and those with long-standing Anemia or heart problems. It is treated by stopping the transfusion, giving oxygen, and using a diuretic medicine to increase urination and lower the plasma volume.
Iron overload. Iron is present in red Blood cells and can build up after multiple Blood transfusions are given. Too much iron can damage the heart, liver, and other organs. Iron overload is usually treated with a chelating agent that binds to excess iron, causing it to be eliminated through the urine.
Infectious disease. The Blood you will receive during a transfusion is extremely safe because the Blood is tested for infectious organisms, and potential donors are carefully screened. However, there is a very small chance that an infectious disease may be transmitted through a Blood transfusion. Hepatitis virus and cytomegalovirus (CMV) are 2 viruses that can be transmitted through Blood transfusion. The human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS), can also be transmitted through Blood.
Be sure to talk with your health care team if you have any questions or concerns about the Blood you will be receiving during your transfusion, how the Blood was tested and prepared, and what side effects might be possible after receiving a transfusion.
June 08, 2023 – Research from the Radiological Society of North America (RSNA) indicates that artificial intelligence (AI) algorithms performed better than the Breast cancer Surveillance Consortium (BCSC) risk model in predicting the five-year risk of the disease.
Data from the Centers for Disease Control and Prevention (CDC) shows that 264,000 women and 2,400 men receive a breast cancer diagnosis annually.
Despite the various methods of predicting breast cancer, such as the BCSC risk model, their use can be taxing. Dig DeeperDeep-Learning Tool Can Predict Lung cancer Risk Within Six Years Genetic Mutation Data Indicates Ovarian cancer Risk Predictive Analytics Model Helps Determine Colon cancer Risk
According to Vignesh A. Arasu, MD, PhD, a Research scientist and practicing radiologist at Kaiser Permanente Northern California, this is mainly because the information they require can be inaccessible or difficult to obtain. However, Arasu noted that technological advances and AI could make the process of evaluating mammograms more efficient.
To compare the abilities of AI to the BCSC model, Arasu conducted a retrospective study that involved negative screening 2D mammograms from Kaiser Permanente Northern California in 2016. From a pool of 324,009 women who were deemed eligible in 2016, mammograms from 13,628 were analyzed. The study also followed the 4,584 patients from the original patient population who received a cancer diagnosis within five years.
Researchers defined three time periods based on when the diagnosis occurred: interval cancer risk, describing diagnoses between zero and one year; future cancer risk, describing diagnoses from between one and five years; and all cancer risk, encompassing the entirety of the five-year period.
Researchers used a total of five AI algorithms for the study, two of which were academic algorithms and three of which were commercially available. After comparing their performance to the abilities of the BCSC risk model, researchers found that the AI algorithms performed better than the standard risk model.
“All five AI algorithms performed better than the BCSC risk model for predicting breast cancer risk at 0 to 5 years,” said Arasu in a press release. “This strong predictive performance over the five-year period suggests AI is identifying both missed cancers and breast tissue features that help predict future cancer development. Something in mammograms allows us to track breast cancer risk. This is the ‘black box’ of AI.”
Beyond this, the AI algorithms presented several other benefits. Researchers also noted that certain AI algorithms performed well in predicting those at risk of interval cancer. This is critical, as this generally requires follow-up mammogram readings.
Also, even AI algorithms that did not have a long training duration performed well.
“We’re looking for an accurate, efficient and scalable means of understanding a women’s breast cancer risk,” said Arasu. “Mammography-based AI risk models provide practical advantages over traditional clinical risk models because they use a single data source: the mammogram itself.”
AI is playing an increasingly significant role in cancer prediction and detection, serving as the foundation of many Research efforts.
A large grant from the National cancer Institute in November 2022 led researchers from the University of California Davis to fuel AI projects to enhance breast cancer screening and risk prediction. Through these efforts, researchers aimed to reduce health disparities.
Often, certain types of regular screening can lead to false positive results. The grant, however, will support researchers as they test whether new AI and imaging features can improve risk prediction models.
It’s hard to believe that 2021 is nearly over! Throughout the year, cancerCare has continued to support the growing and changing needs of those impacted by a cancer diagnosis. We are excited to share a selection highlights and achievements:
In January, we published the updated 2021 edition of our Helping Hand guide. This guide offers information for organizations offering practical and financial support and the 2022 edition will be published soon. In the meantime, search our Online Helping Hand for resources.
Our Pen Pal Program helps older adults reduce feelings of isolation. To mark National Volunteer Month, we interviewed oncology social worker Danielle Saff, MSW, LMSW, and our program partner, Caring for Seniors founder Nina Rawal.
Our first-ever virtual gala raised over $800,000 to support our free programs and services! The event included unforgettable auction items and a performance from Tony Award-winner Laura Benanti.
We partnered with Gryt Health to share the wisdom of one of our social workers, Charlotte Ference, MSW, LMSW, about mental health and coping with cancer.
Our dedicated team planned a full virtual weekend of activities for families coping with the loss of a loved one. cancerCare’s first all-virtual Healing Hearts Family Bereavement Camp was a resounding success!
We took a look back at the first year of our free telephone case management service, helping clients overcome barriers to care.
In August, we launched Magnolia Purpose in Planning™ in partnership with Triage cancer. Magnolia Purpose in Planning™ connects people affected by cancer to practical and legal resources they need to plan for the future.
To celebrate cancer Out Loud’s season 4 launch, we looked back at the program’s beginnings and its future in a two-part interview with staff.
Our CEO, Patricia J. Goldsmith, was named to the Forbes 50 Over 50 Vision List, alongside figures like Geena Davis, Eileen Fisher and Wally Funk.
The cancerCare Young Professionals Committee’s Scholarship Program re-opened for young adults who have lost a parent to cancer. To commemorate the passing of former YPC board member and client Seynabou Ba, we also created The Seynabou Ba Fund thanks to an anonymous donor.
One hundred and forty children and teens received backpacks and school supplies as part of our annual Back-to-School Program.
In October, for Breast cancer Awareness Month, we partnered with Awe Inspired to share information on body image and post-treatment survivorship.
For Lung cancer Awareness Month, Long Island Social Services Director Winfield Boerckel, MSW, MBA, LCSW-R, shared his insights and observations after a 25-year career in social work and lung cancer advocacy. Win will be retiring at the end of this year, and we salute him for a quarter century of serving the lung community!
cancerCare is able to serve thousands of clients across the nation each year thanks to the generosity of our supporters. We are grateful each day for the impact we are able to have on those coping with a cancer diagnosis. If you would like to support our free programs and services, please consider making a donation to cancerCare.
cancer is a formidable adversary that affects millions of lives worldwide. In the face of this daunting challenge, arming oneself with knowledge becomes a powerful weapon. The journey of battling cancer is marked by resilience, hope, and the relentless pursuit of understanding. In this battle, knowledge is not only empowering but also a key to making informed decisions, fostering hope, and ultimately improving the quality of life for those affected by this relentless disease. 🌟🦋
Early Detection and Screening 🕵️♀️🔍The critical role of early cancer detection The importance of regular screenings and diagnostic tests Strategies for raising awareness about cancer screenings
Treatment Options and Innovations 💉🔬The evolving landscape of cancer treatments Promising advancements in Award-call-for-profile/”>Chemotherapy, Conference-registration-euro/”>immunotherapy, and targeted therapies Integrative and complementary approaches to cancer treatment
Support and Coping Strategies 💪🤗Emotional and psychological support for cancer patients and their families Coping mechanisms for dealing with the emotional toll of cancer The significance of support groups and mental well-being
Nutrition and Lifestyle 🥦🏋️♂️The role of a balanced diet in cancer prevention and recovery Exercise and physical activity as part of cancer management Holistic approaches to promoting a healthy lifestyle during and after cancer treatment
cancerResearch and Advocacy 🧪📢The impact of cancerResearch on diagnosis and treatment The role of patient advocacy in advancing cancer care Fundraising and awareness campaigns for cancer-related causes
These subtopics collectively emphasize the power of knowledge in the battle against cancer, shedding light on various aspects of prevention, treatment, and support for those affected by this formidable disease. 🌼🔗
cancer.jpg” data-src=”https://scx2.b-cdn.net/gfx/news/hires/2022/liver-cancer.jpg” data-sub-html=”Credit: Pixabay/CC0 Public Domain”>
October is Liver cancer Awareness Month, which makes this a good time to learn more about risk factors for liver cancer and what you can do to prevent it.
More than 41,000 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. this year, and nearly 30,000 people will die of these diseases, according to the American cancer Society.
Liver cancer is cancer that begins in the cells of your liver, which is a football-sized organ in the upper right portion of your abdomen. The liver is essential for digesting food and ridding your body of toxic substances.
Intrahepatic bile duct cancer, which sometimes is classified as a type of liver cancer, occurs in the parts of the bile ducts within the liver. Bile ducts carry bile, a digestive fluid, and they connect your liver to your gallbladder and small intestine.
Factors that increase the risk of primary liver cancer include:
Chronic infection with HBV or HCV. Chronic infection with the hepatitis B virus (HBV) or hepatitis C virus (HCV) increases your risk of liver cancer.
Cirrhosis. This progressive and irreversible condition causes scar tissue to form in your liver and increases your chances of developing liver cancer.
Certain inherited liver diseases. Liver diseases that can increase the risk of liver cancer include hemochromatosis and Wilson’s disease.
Diabetes. People with this Blood sugar disorder have a greater risk of liver cancer than those who don’t have diabetes.
Nonalcoholic fatty liver disease. An accumulation of fat in the liver increases the risk of liver cancer.
Exposure to aflatoxins. Aflatoxins are poisons produced by molds that grow on crops that are stored poorly. Grains and nuts can become contaminated with aflatoxins and end up in foods made of these products.
Excessive alcohol consumption. Consuming more than a moderate amount of alcohol daily over many years can lead to irreversible liver damage and increase your risk of liver cancer.
Reduce your risk of cirrhosis. Cirrhosis is scarring of the liver, and it increases the risk of liver cancer. You can reduce your risk of cirrhosis if you drink alcohol in moderation, if at all, and maintain a healthy weight.
Get vaccinated against hepatitis B. You can reduce your risk of hepatitis B by receiving the hepatitis B vaccine. The vaccine can be given to almost anyone, including infants, older adults and those with compromised immune systems.
Take measures to prevent hepatitis C. No vaccine for hepatitis C exists, but you can reduce your risk of infection by taking care to avoid unprotected sex with a partner infected with HBV, HCV or any other sexually transmitted infection. Don’t inject illegal drugs. If you do, make sure any needle you use is sterile and don’t share it. And before getting a piercing or tattoo, check out the shops in your area and ask staff members about their safety practices. Needles that are not properly sterilized can spread the hepatitis C virus. Seek treatment for hepatitis B or hepatitis C.
Treatments are available for hepatitis B and hepatitis C infections. Research shows that treatment can reduce the risk of liver cancer. Ask your health care professional about liver cancer screening.
For the general population, screening for liver cancer hasn’t been proved to reduce the risk of dying of liver cancer, and it isn’t generally recommended. People with conditions that increase the risk of liver cancer, including hepatitis B, hepatitis C and liver cirrhosis, might consider screening. Discuss the pros and cons of screening with your health care team. Together you can decide whether screening is right for you based on your risk. Screening typically involves a Blood test and an abdominal ultrasound exam every six months.
Liver cancer: Risk factors and prevention (2023, October 14)
retrieved 15 October 2023
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
As things get more and more desperate in the cancer world the advertising for private treatment and test etc is being ramped up. Naturally, rather than sitting on a never ending waiting list, many people are tempted to take the private route, if they have the funds. In my opinion this is ok for many of the more basic procedures and tests. However cancer is a lot more complex than that, and can throw up situations that nobody could foresee.
Back in 2007 when I was first diagnosed, I did have private healthcare cover, but chose to stay on the NHS path. Of course, things were very different then in cancer, than they are today. With all the complex treatment I have received I know for a fact that I have cost millions so far. Most of that would not have been covered, especially for in excess of 16 years, with ongoing complications. Please have a check through some of the positives and negatives before you make your decision.
cancer Treatment in the UK: Navigating Your Options
A cancer diagnosis leaves you facing many difficult decisions. One of the first is whether to pursue treatment through the NHS or private healthcare. It’s a complex choice with pros and cons to weigh carefully. This in-depth blog examines the key factors to consider when deciding between private and NHS cancer care.
One major advantage of private treatment is more rapid access to tests and specialists. After an urgent GP referral, NHS guidelines say you should start treatment within 62 days. However, waits can extend beyond this target during busy periods, averaging around 80 days. Delays happen due to limited equipment, staff shortages, high demand, and other constraints. With private care, you’ll likely begin the diagnostic process within days or weeks, then swiftly proceed to treatment. This faster timeline provides comfort and can be critical for cancers that are aggressive or fast-spreading.
On the other hand, NHS wait times for common cancer types may be reasonable if you have an early stage, non-urgent case. Waits also depend on your location – certain NHS trusts consistently hit targets, while others lag behind. Weigh your personal risk factors and cancer subtype when deciding if NHS wait times could impact outcomes. Know your rights to initiate private care if the NHS cannot start treatment within 62 days.
Private facilities often provide the latest cancer treatments months before they are available on the NHS. This early access includes emerging immunotherapydrugs, targeted therapies, robotic surgery techniques, advanced cyberknife radiation, and more. By the time NHS funding and approval happens, a new drug or technology could be up to a year old. This NHS delay is due to cost analysis requirements and slower policy change
While cutting edge treatments can extend and improve life for cancer patients, risks and benefits are still being established. The innovative nature means long term effects are unknown. NHS doctors follow strict protocols to provide treatments proven highly effective, although considered “standard” versus “revolutionary”. Discuss all pros and cons of new versus established approaches with specialists to make the best decision for your diagnosis.
Choice of Specialists and Hospitals
With private insurance or self-pay, you can pick any qualified specialist in the UK. This allows shopping around to find experts best suited to treat your cancer type and stage. Check credentials, read reviews, understand success rates. You may even choose facilities like Harley Street clinics or prestigious hospitals like The London oncology Clinic. This flexibility and control over physicians can provide added confidence in your care team.
On the NHS, your specialist is assigned based on location and availability. However, UK oncologists undergo rigorous training and demonstrate extensive knowledge. NHS hospitals also employ strict credentialing and performance standards. While your doctors may not be household names, they have the skills and experience needed to deliver high quality treatment. Seek multiple opinions and factor doctor rapport into your NHS/private decision.
Hotel-Like Amenities and Facilities
Private UK clinics aim to make patients comfortable by providing premium facilities more akin to hotels than hospitals. Expect freshly renovated private rooms, better food options, lounges with coffee bars and snacks, etc. The pleasant aesthetics and surroundings can enhance healing and quality of life during treatment. Additionally, private hospitals invest heavily in the latest cancer screening, imaging, and treatment technology to improve precision.
However, don’t discount NHS capabilities. Critical equipment like PET and CT scanners meet rigorous standards at NHS cancer hubs. What NHS facilities may lack in luxury, they make up for in expertise and capacity to handle complex cases. Still, outdated or overloaded equipment can lead to frustrating delays at times. If your local trust has known equipment shortages, going private may provide better access.
Integrated Support Services
Another private care advantage is access to comprehensive support services all under one roof. This includes counselling, nutrition advice, physical therapy, pain management, wig fittings, support groups and more. Having coordinated specialists makes this holistic care more convenient. NHS providers have been slow to take this integrated approach, but select trusts now offer more robust services for counselling, rehab, and lifestyle needs. Check what’s available through both your local NHS trust and private options.
Costs and Medical Insurance
The most prohibitive downside of private cancer care is cost, with no price regulation. You pay out-of-pocket for all expenses unless you have extensive health insurance. Without insurance, private cancer treatment can soar above £20,000 for testing, surgery, drugs, hospital fees and more. Even low-grade, early cancers often exceed £15,000 privately. Compare this to NHS care which is free at point of use for UK residents.
Many Brits take out medical insurance, but most policies have limits or exclusions for serious illnesses like cancer. Pre-existing conditions may also disqualify you from full coverage. Expect costs for drugs, alternative treatments, travel or clinical trial entry to fall outside policy limits. Read fine print carefully and get cost estimates beforehand.
Weighing Up Your Options
In summary, private cancer care offers faster access, more control over specialists, access to emerging treatments, premium facilities and amenities, and integrated support services. But quality NHS treatment has its own strengths like rigorous standards, highly qualified teams, and avoiding financial strain.
Think critically about your unique diagnosis, risk level, finances and personal priorities. Get multiple opinions on optimal treatment plans. Discuss options frankly with both private and NHS oncologists. This allows making the most informed decision possible on whether private or NHS cancer care better suits your medical and lifestyle needs.
As always these are my own opinions based on personal experiences. Please feel free to share your own below.